Search Options Stock News and Analysis from Schaeffer's

BMY Looks to Launch Higher After Cancer Treatment Approval

https://www.schaeffersresearch.com/content/analysis/2021/06/30/bmy-looks-to-launch-higher-after-cancer-treatment-approval

6/30/2021 9:59 AM

Bristol-Myers Squibb Co (NYSE:BMY) is a global biopharmaceutical company that focuses on the discovery, development, and delivery of medications. The company manufactures prescription pharmaceuticals ...

Biopharmaceutical Stock Flat Despite Upgrade to "Buy"

https://www.schaeffersresearch.com/content/news/2021/04/13/biopharmaceutical-stock-flat-despite-upgrade-to-buy

4/13/2021 9:13 AM

The shares of biopharmaceutical name Bristol-Myers Squibb Co (NYSE:BMY) are up 0.6% at $63.07 in pre-market trading, after Truist Securities upgraded the stock to "buy" from hold," with a price-target...

BMY Flashing Bull Signal Ahead of Earnings

https://www.schaeffersresearch.com/content/analysis/2021/02/01/bmy-flashing-bull-signal-ahead-of-earnings

2/1/2021 2:22 PM

The shares of Bristol-Myers Squibb Co (NYSE:BMY) are up 1.6% at $62.39 at last check, just ahead of the pharmaceutical name's fourth-quarter earnings, due out before the open on Thursday, Feb. 4. In ...

Pharma Stock Signal Has Never Been Wrong

https://www.schaeffersresearch.com/content/analysis/2020/10/28/pharma-stock-signal-has-never-been-wrong

10/28/2020 3:01 PM

The shares of Bristol-Myers Squibb Co (NYSE:BMY) are down 1.7% at $57.73 at last check. And while the pharmaceutical name carries a 10% year-to-date deficit, investors should not turn their backs on ...

MYOK Swings Higher on Buyout Buzz

https://www.schaeffersresearch.com/content/news/2020/10/05/myok-swings-higher-on-buyout-buzz

10/5/2020 11:39 AM

Bristol-Meyers Squibb (BMY) announced this morning that it was buying heart drug developer MyoKardia Inc (NASDAQ:MYOK) for $13 billion, or $225 per share in cash, as a way to boost its portfolio of h...

PEOPLE ALSO SEARCH FOR